EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis

Mei-Chuan Lee, Jheng-Yan Wu, Tsung Yu, Chia-Te Liao, Wei-Ting Chang, Han Siong Toh, Kuo-Chuan Hung, Hui-Chen Su iD

Cardiovascular Drugs and Therapy · 2025

DOI: 10.1007/s10557-024-07620-x ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Mei-Chuan Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Chi-Mei Medical Center, No 901, Zhonghua Rd, Yong Kang District, Tainan City, Taiwan. Hauptthemen laut MEDLINE: Venous Thromboembolism, Anticoagulants, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Chi Mei Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Cancer patients face a four- to sevenfold higher risk of venous thromboembolism (VTE) than the general population. Novel oral anticoagulants (NOACs) provide convenient alternatives to traditional therapies. METHODS: We performed a systematic literature search across PubMed, Embase, and the Cochrane Library, targeting studies that examined the use of NOACs in cancer-associated VTE. The search included randomized controlled trials (RCTs). Selected studies compared NOACs with low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKA) in cancer patients diagnosed with VTE. A meta-analysis using a random-effects model was applied to estimate pooled effect sizes for outcomes. RESULTS: In this meta-analysis, we included 12 RCTs. Results showed NOACs were more effective than LMWH in preventing VTE recurrence (RR 0.66, 95% CI 0.52-0.83, p = 0.0004). Compared with VKAs, NOACs showed no significant difference (RR 0.63, 95% CI 0.34-1.15, p = 0.13). However, this finding is limited by the small patient sample. Major bleeding outcomes were similar between NOACs and LMWH/VKAs (RR 1.24, 95% CI 0.85-1.80, p = 0.28; RR 0.77, 95% CI 0.39-1.53, p = 0.46, respectively). Meta-regression analysis indicated a statistically significant positive correlation between mortality and major bleeding events when comparing NOACs with LMWH (p = 0.049). There was no significant difference in all-cause mortality between patients treated with NOACs and those treated with LMWH (RR 1.04, 95% CI 0.92-1.18, p = 0.54) or VKAs (RR 0.94, 95% CI 0.72-1.23, p = 0.65). CONCLUSION: Meta-analysis shows NOACs, especially factor Xa inhibitors, reduce VTE recurrence in cancer patients more effectively than LMWH. Comparison between NOACs and VKAs is inconclusive due to limited patient data. Further research is needed to assess NOACs' efficacy and safety against VKAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismAnticoagulantsNeoplasmsHumansTreatment OutcomeHeparin, Low-Molecular-WeightHemorrhageRandomized Controlled Trials as TopicAdministration, Oral

Stichwörter der Autor:innen

AnticoagulantCancer-associated VTENOACsVTE

Substanzen

AnticoagulantsHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Department of Pharmacy, Chi-Mei Medical Center, No 901, Zhonghua Rd, Yong Kang District, Tainan City, Taiwan.
  • Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
  • Department of Electrical Engineer, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
  • Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.

ORCID-Profile: Hui-Chen Su

Förderung

  • Chi Mei Medical Center

Zitieren

APA

Lee, M. C., Wu, J. Y., Yu, T., Liao, C. T., Chang, W. T., Toh, H. S., Hung, K. C., & Su, H. C. (2025). Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07620-x

Vancouver

Lee MC, Wu JY, Yu T, Liao CT, Chang WT, Toh HS, et al. Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07620-x

BibTeX
@article{Lee2025,
  author = {Lee, Mei-Chuan and Wu, Jheng-Yan and Yu, Tsung and Liao, Chia-Te and Chang, Wei-Ting and Toh, Han Siong and Hung, Kuo-Chuan and Su, Hui-Chen},
  title = {Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2025},
  doi = {10.1007/s10557-024-07620-x}
}
Kostenlos starten →